Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  
 
 

Our Products

Contact Us

sanofi-aventis Pakistan limited

Registered Office

Plot 23, Sector 22
Korangi Industrial Area
Karachi-74900

Postal Address

P.O. Box 4962
Karachi-74000

Tel: 0800-70707

Content :

Stilnox® (zolpidem)

Stilnox®

Stilnox® Tablet 10 mg 2x10

20% to 30% of the population affected

Insomnia is a combination of unsatisfying sleep and its consequences during the day: irritability, short attention span and inability to concentrate.
Nearly 150 million insomniacs have been identified on the seven leading markets. If left untreated, insomnia can become chronic and may multiply by as much as eight-fold the risk of developing a state of depression, depending on the degree of severity.

An extremely high socio-economic cost

Absenteeism, lower productivity levels, increased consumption of medication, a greater number of accidents, in particular car accidents which are two to three times more frequent for insomniacs, and twice as many hospital stays.
The high cost of insomnia is such that it justifies early treatment.
In the U.S., direct and indirect costs have been evaluated at over 100 billion USD a year.

Many patients still untreated

The percentage of the insomniac population suffering from untreated sleep disorder is large: 73% in the United States, 65% in France, 64% in Japan, according to the 2003 Harris Medical International study.

Treatment of insomnia

The world's leading hypnotic More than 12 billion treatment nights since launch


Already a longstanding market leader in Europe and the United States, Myslee® also became no. 1 in Japan in November 2003.
A new formulation, which offers even better sleep continuity, was filed for approval in the United States in June 2004, in France and Switzerland in November 2004, and will be filed shortly in other European countries and later in Australasia and Latin America.

The only medication with proven efficacy when used "as needed"


Chemically different from benzodiazepines, Stilnox® is distinguished by its selective binding to brain receptors mediating hypnotic activity.
As a result, it rapidly induces sleep that is qualitatively close to natural sleep. Its effects last six to seven hours. It is well tolerated and allows the patient to awaken refreshed. In addition, the risk of dependency, the main drawback of hypnotics, is kept to a minimum when the recommended doses and treatment times are followed.

Updated April 01, 2006

Module :